GenSci161 Injection Clinical Trial Application Accepted by NMPA

Changchun High-Tech announced on August 31 that its controlling subsidiary, Changchun Jinsai Pharmaceutical Co. , Ltd. , received the Acceptance Notice issued by the National Medical Products Administration (NMPA). The clinical trial application for the domestic production of GenSci161 injection, independently developed by Jinsai Pharmaceutical, has been accepted. The injection is a therapeutic biologic product classified as Class 1, intended for the treatment of connective tissue disease-associated interstitial lung disease.